Treatment with either LDN or BMPR1a-Fc led to a significant reduction in osteoclast number and the proportion of bone surface occupied by osteoclasts in myeloma-bearing mice, with osteoclast number also reduced in non-tumour-bearing animals (Fig. 4a–c). This evidence concerns the gene BMPR1A and plasma cell myeloma.